CN106617072A - Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof - Google Patents
Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof Download PDFInfo
- Publication number
- CN106617072A CN106617072A CN201611182538.4A CN201611182538A CN106617072A CN 106617072 A CN106617072 A CN 106617072A CN 201611182538 A CN201611182538 A CN 201611182538A CN 106617072 A CN106617072 A CN 106617072A
- Authority
- CN
- China
- Prior art keywords
- parts
- tablet
- phytosterol
- blood fat
- reducing compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000009472 formulation Methods 0.000 title 1
- 210000004369 blood Anatomy 0.000 claims abstract description 45
- 239000008280 blood Substances 0.000 claims abstract description 45
- 244000068988 Glycine max Species 0.000 claims abstract description 21
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 16
- 239000000787 lecithin Substances 0.000 claims abstract description 16
- 235000010445 lecithin Nutrition 0.000 claims abstract description 16
- 229940067606 lecithin Drugs 0.000 claims abstract description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 10
- 239000004376 Sucralose Substances 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 10
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 10
- 235000019408 sucralose Nutrition 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000005550 wet granulation Methods 0.000 claims abstract description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 16
- 229920002498 Beta-glucan Polymers 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 235000020985 whole grains Nutrition 0.000 claims description 10
- 235000002378 plant sterols Nutrition 0.000 claims description 9
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 235000019640 taste Nutrition 0.000 abstract description 2
- 229920001503 Glucan Polymers 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a phytosterol compound lipid-decreasing formula and a preparation method for a tablet thereof. The formula comprises the following components in parts by weight: 15-70 parts of phytosterol, 5-50 parts of soybean peptide, 5-30 parts of beta-glucosan, 1-20 parts of lecithin, 10-70 parts of mannite, 1-30 parts of maltodextrin, 0.01-1 part of sucralose and 5-30 parts of microcrystalline cellulose. The preparation method for the tablet thereof comprises the following steps: mixing and stirring; performing wet granulation; drying; stabilizing grain size; and pressing into the tablet, thereby acquiring the tablet of the formula. The invention has the beneficial effects that the formula has an excellent lipid-decreasing effect, is capable of effectively reducing the blood lipid level of hyperlipidemia patient and has a lipid-decreasing healthcare function; the tablet prepared according to the preparation method for the tablet tastes nice; the tablet is high in stability.
Description
Technical field
The present invention relates to field of health care food, and in particular to a plant sterols blood fat reducing compound prescription and its tablet preparation side
Method.
Background technology
Blood fat is the general name of the T-CHOL (TC), triglycerides (TG) and lipoid (such as phosphatide) in blood plasma.High fat of blood
Refer to that blood lipid level is too high, be embodied in the rising of TC, TG, LDL-C (LDL-C) concentration level, HDL-C
(HDL-C) concentration level is reduced.
High fat of blood Jing often causes the disease of some serious harm healths, such as atherosclerotic, coronary heart disease, brain blood
Bolt, cerebral hemorrhage, pancreatitis etc., especially the incidence of disease is higher in the middle of the elderly.Therefore, the research of reducing blood lipid is taken much count of both at home and abroad
With treatment.
Phytosterol is conventional blood fat reducing function material, can effectively reduce blood lipid level, and will not produce pair
Effect.But the dissolubility of phytosterol is bad, healthy population is typically smaller than 5% of content in food to its absorptivity, is far below
The absorptivity of cholesterol 35～70%.
Existing plant sterol product or technology, have that phytosterol absorption rate is low, the mode of action is more single, mouth
The shortcomings of sense is poor, tablet stability is poor, it is therefore necessary to improved.
The content of the invention
It is an object of the invention to overcome the weak point of above-mentioned existing product or technology, there is provided a plant sterols are combined
Lipid-loweringing prescription and its method for preparing tablet thereof.
For achieving the above object, the technical scheme that the present invention takes is as follows：One plant sterols blood fat reducing compound prescription, including
Following component：By weight, 15～70 parts of phytosterol, 5～50 parts of Soybean Peptide, 5～30 parts of beta glucan and lecithin 1～
20 parts.
Preferably, also including following component：By weight, 10～70 parts of mannitol, 1～30 part of maltodextrin, three
5～30 parts of 0.01～1 part of chlorine sucrose and microcrystalline cellulose.
Preferably, the soybean peptide molecular weight is 200～3000Dalton.
Preferably, the soybean peptide molecular weight is 200～800Dalton.
Preferably, the beta glucan is from highland barley or oat.
The method for preparing tablet thereof of above-mentioned phytosterol blood fat reducing compound prescription, comprises the following steps：
Step one, takes the phytosterol, Soybean Peptide, beta glucan, lecithin, mannitol, maltodextrin, trichlorine sugarcane
Sugar and microcrystalline cellulose mixing and stirring, obtain mixture；
Step 2, adds ethanol solution to carry out wet granulation in the mixture, obtains wet granular；
Step 3, the wet granular is dried, and obtains dry particl；
Step 4, by the dry particl whole grain is carried out；
Step 5, by whole grain after the dry particl carry out compressing tablet, obtain tablet.
Preferably, the ethanol solution concentration in step 2 is 50～75%.
Preferably, the baking temperature in step 3 is 50～80 DEG C.
Effect of each component is in phytosterol compound antihyperglycemic prescription of the present invention：
Phytosterol：Phytosterol is a kind of lipid active component in many plants such as soybean, corn, chemical constitution with
Cholesterol is similar, and it can reduce cholesterol in the absorption of enteron aisle and suppress the biochemical synthesis of cholesterol, with obvious reducing blood lipid
Effect.
Soybean Peptide：Soybean Peptide is the small molecule amino acid fragment of soybean protein Jing enzymolysis.It can stimulate thyroid hormone
Secretion, promotes cholesterol metabolic to produce bile acid, and bile acid is adsorbed by food fiber, is excreted so as to hinder to courage
The absorption of sterol, plays reduction cholesterol effect.
Beta glucan：Beta glucan is a kind of stickiness polysaccharide, has stronger chela to organic molecules such as cholesterol and bile acids
Suction-operated is closed, and bile and bile acid can be promoted to excrete, effectively reduce LDL-C levels.And, the stickiness of beta glucan
Contribute to extending phytosterol in the holdup time of enteron aisle, increase its absorption rate.
Lecithin：Lecithin is that a kind of phosphatide extracted by physical refining processes from plant or animal is mixed
Thing, main component is phosphatid ylcholine (narrow sense lecithin), lipositol, cephalin (phosphatidyl-ethanolamine), phosphatidic acid etc..Often
There are soybean lecithin and egg yolk lecithin.Lecithin promotes the excretion of bile acid by increasing the operating to cholesterol, with
And the emulsification scavenging action to triglycerides, can effectively reduce people with hyperlipidemia blood lipid level.
The invention has the beneficial effects as follows：The prescription of the present invention is entered using phytosterol, lecithin, Soybean Peptide, beta glucan
Row composite, by the joint effect for reducing fat side of lipid, protide and polysaccharide in the simulation restructuring plant such as soybean and oat
Formula, Synergistic further improves the effect of reducing blood lipid；Meanwhile, the tablet preparation method of the present invention utilizes mannitol, malt
The cooperation of dextrin, Sucralose and microcrystalline cellulose, has not only corrected the disagreeable tastes such as phytosterol and Soybean Peptide, and improves
The stability of tablet and its composition, is more conducive to blood fat reducing compound prescription and plays its efficacy effect.
Specific embodiment
The principle and feature of the present invention are described below, example is served only for explaining the present invention, is not intended to limit
Determine the scope of the present invention.
Embodiment 1
The phytosterol blood fat reducing compound prescription of the present embodiment, including following component：By weight, 15 parts of phytosterol,
5 parts of Soybean Peptide, 5 parts of beta glucan, 1 part of lecithin, 10 parts of mannitol, 1 part of maltodextrin, 0.01 part of Sucralose and crystallite
5 parts of cellulose.
The method for preparing tablet thereof of the phytosterol blood fat reducing compound prescription of the present embodiment, comprises the following steps：
Step one, takes 15 parts of phytosterol, 5 parts of Soybean Peptide, 5 parts of beta glucan, 1 part of lecithin, 10 parts of mannitol, wheat
1 part of bud dextrin, 5 parts of mixing and stirrings of 0.01 part of Sucralose and microcrystalline cellulose, obtain mixture；
Step 2,50% ethanol solution is added in mixture and wet granulation is carried out using wet granulator, is obtained
Wet granular；
Step 3, wet granular is dried using heated-air circulation oven at 50 DEG C, obtains dry particl；
Step 4, dry particl is put into pelletizing machine carries out whole grain；
Step 5, compressing tablet is carried out by the dry particl that whole grain is completed by tablet press machine, obtains tablet.
Embodiment 2
The phytosterol blood fat reducing compound prescription of the present embodiment, including following component：By weight, 30 parts of phytosterol,
20 parts of Soybean Peptide, 15 parts of beta glucan, 10 parts of lecithin, 30 parts of mannitol, 10 parts of maltodextrin, 0.5 part of Sucralose and
15 parts of microcrystalline cellulose.
The method for preparing tablet thereof of the phytosterol blood fat reducing compound prescription of the present embodiment, comprises the following steps：
Step one, takes 30 parts of the phytosterol, 20 parts of Soybean Peptide, 15 parts of beta glucan, 10 parts of lecithin, mannitol
30 parts, 10 parts of maltodextrin, 15 parts of mixing and stirrings of 0.5 part of Sucralose and microcrystalline cellulose, obtain mixture；
Step 2, adds 60% ethanol solution to carry out wet granulation using wet granulator in mixture, obtains wet
Particle；
Step 3, wet granular is dried using heated-air circulation oven at 65 DEG C, obtains dry particl；
Step 4, dry particl is put into pelletizing machine carries out whole grain；
Step 5, compressing tablet is carried out by the dry particl that whole grain is completed by tablet press machine, obtains tablet.
Embodiment 3
The phytosterol blood fat reducing compound prescription of the present embodiment, including following component：By weight, 70 parts of phytosterol,
50 parts of Soybean Peptide, 30 parts of beta glucan, 20 parts of lecithin, 70 parts of mannitol, 30 parts of maltodextrin, 1 part of Sucralose and micro-
30 parts of crystalline cellulose.
The method for preparing tablet thereof of the phytosterol blood fat reducing compound prescription of the present embodiment, comprises the following steps：
Step one, takes 70 parts of the phytosterol, 50 parts of Soybean Peptide, 30 parts of beta glucan, 20 parts of lecithin, mannitol
70 parts, 30 parts of maltodextrin, 30 parts of mixing and stirrings of 1 part of Sucralose and microcrystalline cellulose, obtain mixture；
Step 2, adds 75% ethanol solution to carry out wet granulation using wet granulator in mixture, obtains wet
Particle；
Step 3, wet granular is dried using heated-air circulation oven at 80 DEG C, obtains dry particl；
Step 4, dry particl is put into pelletizing machine carries out whole grain；
Step 5, compressing tablet is carried out by the dry particl that whole grain is completed by tablet press machine, obtains tablet.
Test case (present case adopts the tablet obtained by embodiment 2, temporarily entitled phytosterol blood fat reducing compound piece)：
In order to investigate application effect of the phytosterol blood fat reducing compound piece to blood fat, select《Blood-fat-decreasing functional check
Method》In combined hyperlipidemia familial animal model tested.Take 58 SPF level SD kind male rats to be randomly divided into by body weight
Blank control group and high lipid food group, it is random that high lipid food group presses serum cholesterol (TC) level after 1 week in feeding high lipid food
It is divided into hyperlipidemia model group, low dose group, middle dose group and high dose group, animal continues to give high lipid food, while low dose group,
Middle dose group and high dose group give respectively 0.37,0.73, tablet obtained in 2.20g/kg BW embodiments 2, its dosage is respectively
5,10,30 times of human body recommended amounts, test totally 45 days, result of the test is as follows：
1st, impact of the phytosterol blood fat reducing compound piece to TC
Impact of the phytosterol blood fat reducing compound piece of table 1 to TC
Note：* represents that dosage group compares ＜ 0.05 with hyperlipidemia model group in table 1.
As shown in Table 1：The middle and high dosage group serum TC level of given the test agent is substantially less than hyperlipidemia model group.
2nd, impact of the phytosterol blood fat reducing compound piece to TG
Impact of the phytosterol blood fat reducing compound piece of table 2 to TG
As shown in Table 2：The each dosage group serum TG levels of given the test agent are not apparent from higher than hyperlipidemia model group.
3rd, impact of the phytosterol blood fat reducing compound piece to Serum HDL-C level
Impact of the phytosterol blood fat reducing compound piece of table 3 to Serum HDL-C level
As shown in Table 3：The each dosage group Serum HDL-C level of given the test agent is not apparent from less than hyperlipidemia model group.
4th, impact of the phytosterol blood fat reducing compound piece to serum LDL-C levels
Impact of the phytosterol blood fat reducing compound piece of table 4 to serum LDL-C levels
As shown in Table 4：Given the test agent high dose group serum LDL-C levels are substantially less than hyperlipidemia model group.
The result of summary table 1～4, according to national medicine prison guarantorization [2012] 107《Blood-fat-decreasing functional check
Method》Evaluation method judges that the phytosterol blood fat reducing compound piece auxiliary obtained by embodiment 2 reduces cholesterol function animal experiment
As a result it is positive.Result of the test shows that phytosterol blood fat reducing compound piece has the function of reducing blood lipid.
The foregoing is only presently preferred embodiments of the present invention, not to limit the present invention, all spirit in the present invention and
Within principle, any modification, equivalent substitution and improvements made etc. should be included within the scope of the present invention.
Claims (8)
1. a plant sterols blood fat reducing compound prescription, it is characterised in that including following component：By weight, phytosterol 15
1～20 part of～70 parts, 5～50 parts of Soybean Peptide, 5～30 parts of beta glucan and lecithin.
2. plant sterols blood fat reducing compound prescription according to claim 1, it is characterised in that：Also include following component：
By weight, 10～70 parts of mannitol, 1～30 part of maltodextrin, 0.01～1 part of Sucralose and microcrystalline cellulose 5～
30 parts.
3. phytosterol blood fat reducing compound prescription according to claim 1 and 2, it is characterised in that：The soybean peptide molecular weight
For 200～3000Dalton.
4. phytosterol blood fat reducing compound prescription according to claim 3, it is characterised in that：The soybean peptide molecular weight is
200～800Dalton.
5. phytosterol blood fat reducing compound prescription according to claim 1 and 2, it is characterised in that：The beta glucan source
In highland barley or oat.
6. a kind of method for preparing tablet thereof of phytosterol blood fat reducing compound prescription as claimed in claim 2, it is characterised in that include
Following steps：
Step one, take the phytosterol, Soybean Peptide, beta glucan, lecithin, mannitol, maltodextrin, Sucralose and
Microcrystalline cellulose mixing and stirring, obtains mixture；
Step 2, adds ethanol solution to carry out wet granulation in the mixture, obtains wet granular；
Step 3, the wet granular is dried, and obtains dry particl；
Step 4, by the dry particl whole grain is carried out；
Step 5, by whole grain after the dry particl carry out compressing tablet, obtain tablet.
7. the method for preparing tablet thereof of plant sterols blood fat reducing compound prescription according to claim 6, it is characterised in that step
Ethanol solution concentration in rapid two is 50～75%.
8. the method for preparing tablet thereof of plant sterols blood fat reducing compound prescription according to claim 6, it is characterised in that step
Baking temperature in rapid three is 50～80 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611182538.4A CN106617072A (en) | 2016-12-20 | 2016-12-20 | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611182538.4A CN106617072A (en) | 2016-12-20 | 2016-12-20 | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106617072A true CN106617072A (en) | 2017-05-10 |
Family
ID=58834964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611182538.4A Pending CN106617072A (en) | 2016-12-20 | 2016-12-20 | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106617072A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110897164A (en) * | 2019-12-26 | 2020-03-24 | 广州莱可福生物科技有限公司 | Composition containing phytosterol and application of composition in improving blood sugar |
| CN111011850A (en) * | 2019-12-26 | 2020-04-17 | 广州莱可福生物科技有限公司 | Application of composition containing phytosterol |
| CN111035620A (en) * | 2019-12-25 | 2020-04-21 | 广州莱可福生物科技有限公司 | Auxiliary material composition, phytosterol compound nutrient chewable tablet and preparation method thereof |
| CN114145457A (en) * | 2021-12-10 | 2022-03-08 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006191830A (en) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | Food for suppressing fat accumulation |
| CN103355578A (en) * | 2012-04-06 | 2013-10-23 | 山东香驰集团有限公司 | Soybean peptide nutritional and health tablet |
| CN103766902A (en) * | 2014-01-10 | 2014-05-07 | 杭州海王生物工程有限公司 | Powder with effect of helping to lower blood lipid and preparation method of powder |
| CN103859253A (en) * | 2012-12-18 | 2014-06-18 | 中粮营养健康研究院有限公司 | Soybean peptide chewable tablets and preparation method thereof |
| US20150125568A1 (en) * | 2012-10-17 | 2015-05-07 | Matthew James | Healthy Composition for lowering Cholesterol for use in Foods, Beverages, Health supplements and Medical Foods |
-
2016
- 2016-12-20 CN CN201611182538.4A patent/CN106617072A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006191830A (en) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | Food for suppressing fat accumulation |
| CN103355578A (en) * | 2012-04-06 | 2013-10-23 | 山东香驰集团有限公司 | Soybean peptide nutritional and health tablet |
| US20150125568A1 (en) * | 2012-10-17 | 2015-05-07 | Matthew James | Healthy Composition for lowering Cholesterol for use in Foods, Beverages, Health supplements and Medical Foods |
| CN103859253A (en) * | 2012-12-18 | 2014-06-18 | 中粮营养健康研究院有限公司 | Soybean peptide chewable tablets and preparation method thereof |
| CN103766902A (en) * | 2014-01-10 | 2014-05-07 | 杭州海王生物工程有限公司 | Powder with effect of helping to lower blood lipid and preparation method of powder |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111035620A (en) * | 2019-12-25 | 2020-04-21 | 广州莱可福生物科技有限公司 | Auxiliary material composition, phytosterol compound nutrient chewable tablet and preparation method thereof |
| CN110897164A (en) * | 2019-12-26 | 2020-03-24 | 广州莱可福生物科技有限公司 | Composition containing phytosterol and application of composition in improving blood sugar |
| CN111011850A (en) * | 2019-12-26 | 2020-04-17 | 广州莱可福生物科技有限公司 | Application of composition containing phytosterol |
| CN114145457A (en) * | 2021-12-10 | 2022-03-08 | 黑龙江飞鹤乳业有限公司 | Hypoglycemic composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106617072A (en) | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof | |
| CN101926853B (en) | Medicine composition with function of lowering blood sugar level as well as preparation method and application thereof | |
| CN102860451B (en) | Composite with function of assisting in decreasing blood glucoses and products thereof | |
| CN104126801B (en) | A kind of blood-fat reducing composition containing sterol | |
| TWI291351B (en) | Pharmaceutical composition for lowering blood-sugar | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN1864530A (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN103946019A (en) | Iron-fiber composition, preparation and uses thereof | |
| TWI469785B (en) | Dietary fiber compositions for the treatment of metabolic disease | |
| WO2016000637A1 (en) | Blood-fat reducing composition and application thereof | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| CN105707386A (en) | Burdock composite tablet candy for preventing hypertension and preparation method thereof | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN102600705A (en) | Edible plant dryer | |
| KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
| US20180015132A1 (en) | Method for treatment and prevention of kidney diseases with lotus seedpod extract | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN111280453B (en) | Preparation method of antrodia water-insoluble dietary fiber | |
| CN100364553C (en) | Natural medicinal composition for preparing diabete drug | |
| CN105687218A (en) | Glipizide/acarbose hypoglycemic oral preparation composition and preparation method thereof | |
| CN110302340A (en) | A kind of Chinese medicinal tablet and preparation method thereof with hypolipemic function | |
| CN108186910A (en) | A kind of compound dendrobium officinale piece with effect of lowering blood sugar and preparation method thereof | |
| CN108771084A (en) | A kind of lactalbumin zinc solid beverage and preparation method thereof | |
| CN114949123B (en) | Composition, and preparation method and application thereof | |
| CN106421323A (en) | Drug for treating diabetics and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |